Natera (NASDAQ:NTRA - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $447.91 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Natera Trading Down 3.5 %
Natera stock traded down $5.88 during trading hours on Friday, reaching $162.31. 1,603,736 shares of the company's stock traded hands, compared to its average volume of 1,342,526. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera has a fifty-two week low of $69.74 and a fifty-two week high of $183.00. The firm has a market capitalization of $21.43 billion, a price-to-earnings ratio of -92.22 and a beta of 1.66. The firm's 50 day moving average is $168.06 and its 200-day moving average is $144.78.
Insider Transactions at Natera
In related news, Director Roelof Botha sold 87,473 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the transaction, the director now directly owns 1,224,787 shares of the company's stock, valued at approximately $207,135,977.44. This trade represents a 6.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Fesko sold 663 shares of the firm's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 295,772 shares of company stock valued at $49,741,699 in the last ninety days. 7.60% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on NTRA. Morgan Stanley increased their price target on shares of Natera from $132.00 to $176.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th. Robert W. Baird increased their price target on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. TD Cowen increased their price target on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $170.94.
Check Out Our Latest Stock Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
